SmithKline Beecham LYMErix Posts $18 Mil. In First Quarter Sales
Executive Summary
SmithKline Beecham's Lyme disease vaccine is off to a "solid" start in the U.S., the company said.You may also be interested in...
GSK Lymerix Withdrawn: Production Stopped, Inventory To Be Discarded
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Need a specific report? 1000+ reports available
Buy Reports